Work

First-in-Class Targeted Protein Degrader of MLLT1/3 for the Treatment of Advanced AML and ALL Including Menin Inhibitor Resistant / Refractory Disease

Year: 2024

Type: conference-abstract

Source: Blood

DOI: 10.1182/blood-2024-210052

Authors: John Pollard, Graham Craggs, Gillian Farnie, Matthew Fawkes, Fenella Gross, Joe Harman, Marta Llorca-Cardenosa, Sarah Major, Alison Maloney, Thomas A Milne, Iain Simpson

Institutions: The Francis Crick Institute, University of Oxford, MRC Weatherall Institute of Molecular Medicine, MRC Molecular Haematology Unit

Language: English

Topic: Protein Degradation and Inhibitors

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4405042348

Cites:

Cited by:

Related to: 10